悦康藥業(688658.SH):控股股東、實控人及董事關志寬等延長股份鎖定期
格隆匯 2 月 3日丨悦康藥業(688658.SH)公佈,公司控股股東阜陽京悦永順信息諮詢有限公司、股東霍爾果斯三榮股權投資管理合夥企業(有限合夥)、霍爾果斯德峯股權投資管理合夥企業(有限合夥)、霍爾果斯錦然股權投資管理合夥企業(有限合夥)、霍爾果斯德仁股權投資管理合夥企業(有限合夥)、霍爾果斯雨潤景澤股權投資管理合夥企業(有限合夥)、霍爾果斯合和股權投資管理合夥企業(有限合夥)、霍爾果斯匯龍股權投資管理合夥企業(有限合夥)、阜陽宇達商務信息諮詢有限公司、實際控制人於偉仕、馬桂英、于飛及於鵬飛合計持有公司股份24540萬股,佔公司總股本的54.53%,鎖定期延長6個月至2024年6月23日。
公司董事關志寬持有公司股份0.07萬股,佔公司總股本的0.0002%,鎖定期延長6個月至2022年6月23日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.